Helicobacter pylori resistance;Helicobacter pylori-resistens

Ugeskrift for Laeger

Volumn 172, Issue 20, 2010, Pages

  Alimoradi, Jalal ^a   Rasmussen, Lone ^a   Andersen, Leif Percival ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

DRUG EFFECT; GENETICS; HEALTH; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PREVALENCE; REVIEW; STOMACH ULCER;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; PREVALENCE; STOMACH ULCER; WORLD HEALTH;

EID: 77953453475     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Versalovic J. Helicobacter pylori - Pathology and diagnostic strategies. Am J Clin Pathol 2003;119:403-12.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
3. Andersen LP, Kiilerick S, Pedersen G et al. An analysis of seven different methods to diagnose Helicobacter pylori infections. Scand J Gastroenterol 1998;33:24-30.
4. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
5. Gisbert JP, Pajares JM. Helicobacter pylori »rescue« therapy after failure of two eradication treatments. Helicobacter 2005;10:363-72.
6. Glupczynski Y, Megraud F, Lopez-Brea M et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3.
7. Petersen AM, Gjode P, Vinge OD et al. Helicobacter pylori antimicrobial resistance and risk factors in Denmark 1998-2004: no need for concern? Helicobacter 2006;11:210-1.
8. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997;11 Suppl 1:43-53.
9. Meyer JM, Silliman NP, Wang W et al. Risk factors for Helicobacter pylori resistance in the United States. Ann Intern Med 2002;136:13-24.
10. Mendonca S, Ecclissato CC, Sartori MS et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline, and furazolidone in Brazil. Gastroenterol 2000;118:A1274.
11. Frenck RW, Clemens J. Helicobacter in the developing world. Micr Infect 2003;5:705-13.
12. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90.
13. Debetsossenkopp YJ, Namavar F, Maclaren DM. Effect of an Acidic Environment on the Susceptibility of Helicobacter Pylori to Trospectomycin and Other Antimicrobial Agents. Eur J Clin Microbiol Infect Dis 1995;14:353-5.
14. Andersen LP, Colding H, Kristiansen JE. Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate. Int J Antimicrob Agents 2000;14:231-4.
15. Chen M, Jensen B, Zhai L et al. Nizatidine and omeprazole enhance the effect of metronidazole on Helicobacter pylori in vitro. Int J Antimicrob Agents 2002;19:195-200.
16. Graham DY, Hammoud F, El-Zimaity HMT et al. Meta-analysis: proton pump inhibitor or H-2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:1229-36.
17. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11:27-33.
18. Hojo M, Miwa H, Nagahara A et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
19. Laheij RJF, van Rossum LGM, Jansen JBMJ et al. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999;13:857-64.
20. Peterson WL, Ciociola AA, Sykes DL et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996;10:251-61.
21. Sung JJ, Chan FK, Wu JC et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Aliment Pharmacol Ther 1999;13:1079-84.
22. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the maastricht III consensus report. Gut 2007;56:772-81.
23. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
24. Ecclissato C, Marchioretto MAM, Mendonca S et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 2002;7:53-9.
25. van der Wouden EJ, Thijs JC, van Zwet AA et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
26. Houben MH, van de BD, Hensen EF et al. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55.
27. Goodwin A, Kersulyte D, Sisson G et al. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 1998;28:383-93.
28. Versalovic J, Shortridge D, Kibler K et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-80.
29. Stone GG, Shortridge D, Versalovic J et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 1997;41:712-4.
30. Dore MP, Graham DY, Sepulveda AR. Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Helicobacter 1999;4:154-61.
31. Okamoto T, Yoshiyama H, Nakazawa T et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother 2002;50:849-56.
32. Gerrits MM, de Zoete MR, Arents NL et al. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 2002;46:2996-3000.
33. Moore RA, Beckthold B, Wong S et al. Nucleotide-sequence of the gyra gene and characterization of ciprofloxacin-resistant mutants of Helicobacter-Pylori. Antimicrob Agents Chemother 1995;39:107-11.
34. Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999;116:804-12.
35. Sougioultzis S, Lee CK, Alsahli M et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002;21:194-201.
36. Kotloff KL, Sztein MB, Wasserman SS et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001;69:3581-90.
37. Metzger WG, Mansouri E, Kronawitter M et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004;22:2273-7.
38. Ruggiero P, Peppoloni S, Rappuoli R et al. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microb Infect 2003;5:749-56.
39. Rasmussen L, Christensen M, Chen M et al. Susceptibility of Helicobacter pylori to sucralfate, ibuprofen, and artesunate. Helicobacter 2007;12:410.
40. Fahey JW, Haristoy X, Dolan PM et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA 2002;99:7610-5.